Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005659700
Fri, 24.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 24 March 2023. The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing its legal form. The dualistic management system, consisting of an Executive Board as the management body and a Super [ … ]
Thu, 23.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 23 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed FY 2022 with sales of 222.3 million EUR. Net income for the year rose by around 20% compared to the previous year's figure adjusted for special effects and reached 29.3 million EUR, which corresponds to earnings per share of 1.41 EUR. Based on these figures, Executiv [ … ]
Thu, 23.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 23 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed FY 2022 with sales of 222.3 million EUR. Net income for the year rose by around 20% compared to the previous year's figure adjusted for special effects and reached 29.3 million EUR, which corresponds to earnings per share of 1.41 EUR. Based on these figures, Executiv [ … ]
Fri, 03.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 3 March 2023. Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043.
[ … ]
Fri, 03.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 3 March 2023. Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043.
[ … ]
Wed, 01.02.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting. It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical [ … ]
Wed, 01.02.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting. It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical [ … ]
Tue, 20.12.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20.12.2022. Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). She replaces sinologist Jutta Ludwig, who will move to the Executive Board of Eckert & Ziegler AG as Asia Repre [ … ]
Tue, 20.12.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20.12.2022. Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). She replaces sinologist Jutta Ludwig, who will move to the Executive Board of Eckert & Ziegler AG as Asia Repre [ … ]
Tue, 08.11.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 November 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in the same period of the previous year, in which the sale and associated deconsolidation of the tumor irr [ … ]